Skip to content

A Prospective Clinical Study On A Total Hip Resurfacing System

A Prospective Clinical Study On A Total Hip Resurfacing System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00604734
Enrollment
280
Registered
2008-01-30
Start date
2004-10-31
Completion date
2012-10-31
Last updated
2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Avascular Necrosis

Brief summary

This prospective clinical study is to demonstrate the efficacy and safety of ReCap Total Hip Resurfacing System.

Detailed description

The study is designed as a prospective, multi-center, non-randomized study. It is designed to evaluate the effects of metal-on-metal acetabular articulating bearing surfaces. The device will be used in conjunction with a cemented metal femoral resurfacing prosthesis. The objective of this clinical investigation is to evaluate the safety and effectiveness of the metal-on-metal Recap Total Resurfacing System. Performance will be assessed trough Harris Hip Score, radiographic evaluation at various postoperative visits. Adverse events and revisions will be documented for safety assessments. Primary endpoints: * Total Harris hip score * Device revisions or removals Secondary endpoints: * Total Harris hip score * Radiographic changes as evidenced by: I. Acetabular component migration, change in angle of inclination or presence of osteolysis II. Femoral component subsidence, femoral neck Fracture or presence of osteolysis

Interventions

This is a hip resurfacing system.

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patients with a preoperative Total Harris Hip Score of \< 70 2. Conservative treatment has proven unsuccessful 3. Primary hip surgery 4. Patients requiring hip resurfacing for degenerative joint disease (inflammatory or non- inflammatory) or any of the composite diagnoses of: 1. Osteoarthritis 2. Avascular necrosis 3. Legg Perthes 4. Rheumatoid Arthritis 5. Juvenile Rheumatoid Arthritis 6. Systemic Lupus Erythematosus 7. Developmental Dysplasia, which does not prevent stable acetabular reconstruction 8. Post traumatic arthritis S. Patients at least 18 years of age 6\. Patients of all races and gender 7. Patients who are able to follow post-operative care instructions 8. Patients who are willing and able to return for scheduled follow-up evaluations 9. Patient has signed the IRB approved Informed Consent Form

Exclusion criteria

1. Patients with a preoperative Total Harris Hip Score of \> 70 2. Previous prosthetic hip replacement device (including other surface arthroplasty, endoprosthesis,etc) in the operative hip 3. Contralateral hip prosthesis (total hip replacement or surface replacement),including staged or simultaneous procedures 4. Developmental dysplasla, which prevents stable acetabular reconstruction 5. Patients with previous Girdlestone procedures 6. Patients with above knee amputation of the contralateral and/or ipsilateral leg 7. Severe osteoarthritis or marked bone loss,which would preclude proper fixation of the prosthetic device(s) 8. Active or suspected systemic or localized Infection 9. Parkinson's or Alzheimer's Disease 10. Patients with severe instability or deformity of the ligaments and/or surrounding soft tissue,which would preclude stability of the prosthesis 11. Patients less than 18 years of age 12. Patients with condition(s) that may Interfere with the survival of the femoral resurfacing or acetabular replacements or their outcomes,including Paget's Disease, Charcot's Disease, Sickle Cell Anemia or traits Severe osteoporosis compromising bone stock (I.e.Dorr type C bone Lower extremity muscular atrophy Neuromuscular disease 13. Patients with a clinical conditions that may limit follow-up,including: immunocompromised conditions, hepatitis, active tuberculosis, neoplastic disease, chronic renal failure, organ transplant recipients, known terminal disease process 14. Patients with a fusedhip 15. Patients with metal allergy or hypersensitivity 16. Participation in a study of any investigational product (drug or device) within the past 12 months 17. Prisoners,known drug or alcohol abuser,or mentally incompetent individuals 18. Systemic steroids within 6 months 19. Patients with a known malignancy 20. Patients who are pregnant

Design outcomes

Primary

MeasureTime frame
Harris Hip Score, Device Revision/Removal, Radiographic Evaluation2 years postoperative

Secondary

MeasureTime frame
ComplicationsAnytime

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026